PERIPHERAL T CELLS LYMPHOMA (PTCL)
Clinical trials for PERIPHERAL T CELLS LYMPHOMA (PTCL) explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T CELLS LYMPHOMA (PTCL) trials appear
Sign up with your email to follow new studies for PERIPHERAL T CELLS LYMPHOMA (PTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo offers hope for patients with aggressive lymphoma
Disease control Recruiting nowThis study tests a new mix of three drugs—zeprumetostat, azacitidine, and mitoxantrone hydrochloride liposome—in adults whose peripheral T-cell lymphoma has come back or not responded to earlier treatments. About 26 people will receive up to 6 cycles of the combination, then up t…
Matched conditions: PERIPHERAL T CELLS LYMPHOMA (PTCL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 17, 2026 07:38 UTC
-
New hope for Hard-to-Treat lymphoma: platform trial launches
Knowledge-focused Recruiting nowThis study is testing new drugs or drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The main goal is to gather early information on safety and effectiveness to help design better future studies. About 49 adults will ta…
Matched conditions: PERIPHERAL T CELLS LYMPHOMA (PTCL)
Phase: PHASE1, PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Knowledge-focused
Last updated May 11, 2026 20:46 UTC